Q2 2019 13F Holders as of 30 Jun 2019
-
Type / Class
-
Equity / Ordinary Shares, par value GBP 0.001 per share
-
Shares outstanding
-
1,571,428,571
-
Total 13F shares
-
68,201,500
-
Share change
-
-1,242,868
-
Total reported value
-
$274,160,898
-
Price per share
-
$4.02
-
Number of holders
-
52
-
Value change
-
-$5,116,443
-
Number of buys
-
16
-
Number of sells
-
28
Institutional Holders of Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) as of Q2 2019
As of 30 Jun 2019,
Adaptimmune Therapeutics PLC - Ordinary Shares, par value GBP 0.001 per share (ADAPY) was held by
52 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
68,201,500 shares.
The largest 10 holders included
Matrix Capital Management Company, LP, NEA Management Company, LLC, Capital World Investors, BAILLIE GIFFORD & CO, Man Group plc, FMR LLC, WELLINGTON MANAGEMENT GROUP LLP, ORBIMED ADVISORS LLC, MILLENNIUM MANAGEMENT LLC, and Rock Springs Capital Management LP.
This page lists
52
institutional shareholders reporting positions in this security
for the Q2 2019 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.